Summary
- Sigilon Therapeutics has filed proposed terms for its $101 million U.S. IPO.
- The firm is advancing programs to treat blood, lysosomal storage and other diseases.
- SGTX has produced a positive initial result with its first trial patient, has a strong collaboration relationship with Eli Lilly and the IPO appears reasonably priced.
- For life science investors with a patient hold time frame, the IPO is worth considering.
- Looking for more investing ideas like this one? Get them exclusively at IPO Edge. Get started today »
Quick Take
Sigilon Therapeutics (SGTX) intends to raise $101 million from the sale of its common stock in an IPO, according to an amended registration statement.
The company is developing treatment options for blood disorders and other diseases.
SGTX has produced promising early results, has a significant major pharma collaboration and solid investor group.
For life science investors with a very patient hold time frame, the IPO is worth a close look.
Company & Technology
Cambridge, Massachusetts-based Sigilon was founded to develop its Shielded Living Therapeutics platform which uses advanced techniques to create therapeutic molecules for the treatment of rare blood disorders, lysosomal storage diseases and endocrine diseases.
Management is headed by Rogerio Vivaldi Coelho, MD., who has been with the firm since 2018 and was previously EVP and Chief Global Therapeutics Officer at Bioverativ until it was acquired by Sanofi in 2018.
Below is a brief overview video of Sigilon's approach:
